Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af BGB-16673 sammenlignet med efterforskerens valg hos deltagere med kronisk lymfocytisk leukæmi, der tidligere var udsat for både Bruton tyrosinkinase (BTK) og B-celle leukæmi/lymfom 2 protein (BCL2) inhibitorer (CaDAnCe-302)

9. november 2026 opdateret af: BeOne Medicines

En fase 3, open-label, randomiseret undersøgelse af BGB-16673 sammenlignet med efterforskerens valg (idelalisib plus rituximab eller bendamustine plus rituximab eller venetoclax plus rituximab-tilbagetrækning) hos patienter med kronisk lymfocytisk leukemi, der var tidligere udsat for både BTK og BCL2-inhibitor

The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

CLL (chronic lymphocytic leukemia) and SLL (small lymphocytic lymphoma) are slow-growing blood cancers that affect the same type of white blood cell (called B lymphocytes). They are considered different forms of the same disease. CLL mainly occurs in the blood and bone marrow, while SLL mainly affects the lymph nodes.

Tacabrutideg is a type of medicine called a BTK degrader. BTK (Bruton's tyrosine kinase) is a protein that helps cancer cells survive. Tacabrutideg is designed to attach to the BTK protein and tag it for removal, so that the body's own cellular "clean-up" system breaks it down and clears it away. When more BTK is removed from the body, it interferes with the signals needed for the cancer cells to multiply and survive and may also help overcome resistance caused by certain changes in BTK.

The purpose of this study is to test if tacabrutideg is safe and if it works in adults with CLL or SLL. The main goal of the study is to find the amount of time participants live without their disease getting worse after starting the study treatment.

This study has two treatment groups. Participants will be randomly assigned by chance, to one of the treatment groups. Participants and the study doctors will know what treatment is received during the study.

The study will enroll approximately 250 adults at multiple centers worldwide with CLL or SLL. The overall time to participate in this study is 36 months. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

250

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Caba, Argentina, CP1114
        • Rekruttering
        • FUNDALEU
      • Caba, Argentina, C1431
        • Rekruttering
        • CEMIC
      • Caba, Argentina, 1425
        • Rekruttering
        • Hospital Aleman
      • Ciudad Autonoma Buenos Aires, Argentina, 1413
        • Rekruttering
        • Hospital Italiano de Buenos Aires
      • Ciudad Autonoma Buenos Aires, Argentina, 1426
        • Rekruttering
        • Instituto Alexander Fleming (Iaf)
      • San Miguel de Tucumán, Argentina, 4000
        • Rekruttering
        • Cice 9 de Julio Sanatorio 9 de Julio
    • New South Wales
      • Concord, New South Wales, Australien, NSW 2139
        • Rekruttering
        • Concord Repatriation General Hospital
      • Gosford, New South Wales, Australien, NSW 2250
        • Rekruttering
        • Gosford Hospital
      • Port Macquarie, New South Wales, Australien, NSW 2444
        • Rekruttering
        • Port Macquarie Base Hospital
      • Randwick, New South Wales, Australien, NSW 2031
        • Rekruttering
        • Prince of Wales Hospital
    • Queensland
      • Toowoomba, Queensland, Australien, QLD 4350
        • Rekruttering
        • Toowoomba Hospital
    • South Australia
      • Bedford PK, South Australia, Australien, SA 5042
        • Rekruttering
        • Flinders Medical Centre
    • Victoria
      • Melbourne, Victoria, Australien, VIC 3004
        • Rekruttering
        • The Alfred Hospital
    • Western Australia
      • West Perth, Western Australia, Australien, WA 6005
        • Rekruttering
        • Perth Blood Institute
      • Belo Horizonte, Brasilien, 30110-022
        • Rekruttering
        • CETUS
      • Brasília, Brasilien, 70200-730
        • Rekruttering
        • Hospital Sirio Libanes Brasilia
      • Curitiba, Brasilien, 81520-060
        • Rekruttering
        • Hospital Erasto Gaertner
      • Florianópolis, Brasilien, 88020-210
        • Rekruttering
        • Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen)
      • Joinville, Brasilien, 89201-260
        • Rekruttering
        • Instituto Joinvilense de Hematologia E Oncologia
      • Niterói, Brasilien, 24020-096
        • Rekruttering
        • Complexo Hospitalar de Niteroi
      • Novo Hamburgo, Brasilien, 93510-223
        • Rekruttering
        • Vida Hematologia
      • Porto Alegre, Brasilien, 90110-270
        • Rekruttering
        • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
      • Rio de Janeiro, Brasilien, 22250-040
        • Rekruttering
        • Oncoclinicas Rio de Janeiro Sa
      • Rio de Janeiro, Brasilien, 22061-080
        • Rekruttering
        • Hospital Sao Lucas Dasa Oncologia
      • Salvador, Brasilien, 41253-190
        • Rekruttering
        • Hospital Sao Rafael (Rede Dor)
      • São Paulo, Brasilien, 05652-900
        • Rekruttering
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brasilien, 04014-002
        • Rekruttering
        • Instituto Brasileiro de Controle Do Cancer
      • São Paulo, Brasilien, 01401-004
        • Rekruttering
        • Instituto Dor de Pesquisa E Ensino Sao Paulo
      • Vitória, Brasilien, 29043-260
        • Rekruttering
        • Hospital Santa Rita de Cassia Afecc
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Rekruttering
        • Juravinski Cancer Centre
      • London, Ontario, Canada, N6A 5W9
        • Rekruttering
        • London Health Sciences Centre
      • Ottawa, Ontario, Canada, K1H 8L6
        • Rekruttering
        • The Ottawa Hospital Cancer Centre
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • Rekruttering
        • Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre
      • Montreal, Quebec, Canada, QC H3t 1E2
        • Rekruttering
        • Jewish General Hospital
      • SaintJerome, Quebec, Canada, J7Z 5T3
        • Rekruttering
        • Unite de Recherche Clinique Du Cisss Des Laurentides
      • Aberdeen, Det Forenede Kongerige, AB25 2ZN
        • Rekruttering
        • Aberdeen Royal Infirmary
      • Birmingham, Det Forenede Kongerige, B9 5SS
        • Rekruttering
        • Birmingham Heartlands Hospital
      • Bournemouth, Det Forenede Kongerige, BH7 7DW
        • Rekruttering
        • The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
      • London, Det Forenede Kongerige, SW3 6JJ
        • Rekruttering
        • Royal Marsden Hospital
      • London, Det Forenede Kongerige, NW1 2PG
        • Rekruttering
        • University College Hospital
      • Southampton, Det Forenede Kongerige, SO16 6YD
        • Rekruttering
        • Southampton General Hospital
    • Arkansas
      • Jonesboro, Arkansas, Forenede Stater, 72401
        • Rekruttering
        • St Bernards Medical Center
    • California
      • Los Angeles, California, Forenede Stater, 90095-3075
        • Rekruttering
        • UCLA Department of Medicine Hematologyoncology
      • San Diego, California, Forenede Stater, 92103-2106
        • Rekruttering
        • Scripps Prebys Cancer Center
      • Whittier, California, Forenede Stater, 90602
        • Rekruttering
        • Pih Health Whittier Hospital
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80012-5405
        • Rekruttering
        • Rocky Mountain Cancer Centers (Williams) Usor
      • Golden, Colorado, Forenede Stater, 80401
        • Rekruttering
        • Intermountain Health Lutheran Hospital Cancer Center of Colorado
    • Florida
      • Fort Myers, Florida, Forenede Stater, 33912
        • Rekruttering
        • Florida Oncology and Hematology
      • Jacksonville, Florida, Forenede Stater, 32207-8432
        • Rekruttering
        • Baptist Md Anderson Cancer Center
      • Weston, Florida, Forenede Stater, 33331-3609
        • Rekruttering
        • Cleveland Clinic Florida
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322-1013
        • Rekruttering
        • Emory University Winship Cancer Institute
      • Atlanta, Georgia, Forenede Stater, 30342
        • Rekruttering
        • Northside Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, Forenede Stater, 70808-4365
        • Rekruttering
        • Our Lady of the Lake Hospital
    • Maryland
      • Bethesda, Maryland, Forenede Stater, 20817-7847
        • Rekruttering
        • American Oncology Partners of Maryland Pa
    • Michigan
      • Grand Rapids, Michigan, Forenede Stater, 49503-2560
        • Rekruttering
        • Corewell Health the Michigan Cancer Consortium
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55455-0341
        • Rekruttering
        • University of Minnesota
    • Missouri
      • Chesterfield, Missouri, Forenede Stater, 63017
        • Rekruttering
        • St Lukes Center For Cancer Care
      • Springfield, Missouri, Forenede Stater, 65807-5288
        • Rekruttering
        • Oncology Hematology Associates
    • Montana
      • Billings, Montana, Forenede Stater, 59102-6746
        • Rekruttering
        • St Vincent Frontier Cancer Center
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68130-2042
        • Rekruttering
        • Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
    • New York
      • New York, New York, Forenede Stater, 10065-6800
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center Mskcc
      • Shirley, New York, Forenede Stater, 11967
        • Rekruttering
        • New York Cancer and Blood Specialists
      • Syracuse, New York, Forenede Stater, 13210-2306
        • Rekruttering
        • Suny Upstate Medical University
      • Westbury, New York, Forenede Stater, 11590-5119
        • Rekruttering
        • Optum Medical Care, Pc
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106-1716
        • Rekruttering
        • University Hospitals
      • Dayton, Ohio, Forenede Stater, 45415
        • Rekruttering
        • Dayton Physician Network
    • Oregon
      • Eugene, Oregon, Forenede Stater, 97401
        • Rekruttering
        • Oncology Associates of Oregon Willamette Valley Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15224
        • Rekruttering
        • West Penn Hospital
      • York, Pennsylvania, Forenede Stater, 17403-5049
        • Rekruttering
        • Cancer Care Associates of York
    • Texas
      • Temple, Texas, Forenede Stater, 76508-0001
        • Rekruttering
        • Baylor Scott and White Health Medical Center Temple
      • Tyler, Texas, Forenede Stater, 75702-7522
        • Rekruttering
        • Texas Oncology Tyler
      • Amsterdam, Holland, 1081 HV
        • Rekruttering
        • Amsterdam Umc Vu Mc
      • Bari, Italien, 70124
        • Rekruttering
        • Irccs Istituto Tumori Giovanni Paolo Ii
      • Florence, Italien, 50134
        • Rekruttering
        • Aou Careggi, Servizio Sanitario Toscana
      • Milan, Italien, 20132
        • Rekruttering
        • Ospedale San Raffaele
      • Milan, Italien, 20122
        • Rekruttering
        • Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico
      • Naples, Italien, 80131
        • Rekruttering
        • Azienda Ospedaliera Universitaria Federico Ii
      • Novara, Italien, 28100
        • Rekruttering
        • Aou Maggiore Della Carita
      • Pavia, Italien, 27100
        • Rekruttering
        • Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
      • Perugia, Italien, 6129
        • Rekruttering
        • Ospedale Santa Maria Della Misericordia
      • Roma, Italien, 00168
        • Rekruttering
        • Fondazione Policlinico Universitario Agostino Gemelli
      • Kumamoto, Japan, 860-8556
        • Rekruttering
        • Kumamoto University Hospital
      • Okayama, Japan, 701-1192
        • Rekruttering
        • National Hospital Organization Okayama Medical Center
      • Osaka, Japan, 545-8586
        • Rekruttering
        • Osaka Metropolitan University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 464-8681
        • Rekruttering
        • Aichi Cancer Center Hospital Clinical Oncology
    • Chiba
      • Chiba, Chiba, Japan, 260-8717
        • Rekruttering
        • Chiba Cancer Center
    • Ehime
      • Matsuyama, Ehime, Japan, 791-0280
        • Rekruttering
        • Nho Shikoku Cancer Center
    • Hiroshima
      • Hiroshima, Hiroshima, Japan, 730-8619
        • Rekruttering
        • Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 064-0804
        • Rekruttering
        • Aiiku Hospital
    • Hyōgo
      • AmagasakiCity, Hyōgo, Japan, 660-8550
        • Rekruttering
        • Hyogo Prefectural Amagasaki General Medical Center
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japan, 890-8520
        • Rekruttering
        • Kagoshima University Hospital
    • Kyoto
      • KyotoShi, Kyoto, Japan, 602-8566
        • Rekruttering
        • University Hospital, Kyoto Prefectural Univ of Medicine
    • Miyagi
      • Sendai, Miyagi, Japan, 980-8574
        • Rekruttering
        • Tohoku University Hospital
    • Niigata
      • Niigata, Niigata, Japan, 951-8520
        • Rekruttering
        • Niigata University Medical and Dental Hospital
    • Okayama-ken
      • Kurashikishi, Okayama-ken, Japan, 710-8602
        • Rekruttering
        • Kurashiki Central Hospital
    • Osaka
      • Hirakata, Osaka, Japan, 573-1191
        • Rekruttering
        • Kansai Medical University Hospital
      • Sakai, Osaka, Japan, 590-0197
        • Rekruttering
        • Kindai University Hospital
    • Saitama
      • Kawagoeshi, Saitama, Japan, 350-8550
        • Rekruttering
        • Saitama Medical Center
    • Tokyo
      • Bunkyoku, Tokyo, Japan, 113-8677
        • Rekruttering
        • Tokyo Metropolitan Komagome Hospital
      • Shinagawaku, Tokyo, Japan, 141-0022
        • Rekruttering
        • Ntt Medical Center Tokyo
      • Brzozów, Polen, 36-200
        • Rekruttering
        • Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
      • Katowice, Polen, 40-519
        • Rekruttering
        • Pratia Onkologia Katowice
      • Krakow, Polen, 30-727
        • Rekruttering
        • Pratia McM Krakow
      • Lodz, Polen, 93-510
        • Rekruttering
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
      • Lublin, Polen, 20-090
        • Rekruttering
        • Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
      • Wroclaw, Polen, 50-367
        • Rekruttering
        • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
    • Busan Gwang'yeogsi
      • Seogu, Busan Gwang'yeogsi, Sydkorea, 49201
        • Rekruttering
        • Dong A University Hospital
    • Daegu Gwang'yeogsi
      • Junggu, Daegu Gwang'yeogsi, Sydkorea, 41944
        • Rekruttering
        • Kyungpook National University Hospital
    • Gyeonggi-do
      • IlsandongGu GoyangSi, Gyeonggi-do, Sydkorea, 10408
        • Rekruttering
        • National Cancer Center (Korea)
    • Jeonnam-Gwangju S.M. City
      • HwasunGun, Jeonnam-Gwangju S.M. City, Sydkorea, 58128
        • Rekruttering
        • Chonnam National University Hwasun Hospital
    • Seoul Teugbyeolsi
      • GangnamGu, Seoul Teugbyeolsi, Sydkorea, 06351
        • Rekruttering
        • Samsung Medical Center
      • SeochoGu, Seoul Teugbyeolsi, Sydkorea, 06591
        • Rekruttering
        • The Catholic University of Korea, Seoul St Marys Hospital
      • Seoul, Seoul Teugbyeolsi, Sydkorea, 03080
        • Rekruttering
        • Seoul National University Hospital
      • Brno, Tjekkiet, 625 00
        • Rekruttering
        • Fakultni Nemocnice Brno
      • Hradec Králové, Tjekkiet, 500 03
        • Rekruttering
        • Fakultni Nemocnice Hradec Kralove
      • Ostrava, Tjekkiet, 708 00
        • Rekruttering
        • Fakultni Nemocnice Ostrava
      • Prague, Tjekkiet, 10000
        • Rekruttering
        • Vseobecna Fakultni Nemocnice V Praze
      • Ankara, Tyrkiet (Türkiye), 6500
        • Rekruttering
        • Gazi University
      • Ankara, Tyrkiet (Türkiye), 06200
        • Rekruttering
        • Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
      • Balçova, Tyrkiet (Türkiye), 35330
        • Rekruttering
        • Dokuz Eylul University
      • Dokuma, Tyrkiet (Türkiye), 07025
        • Rekruttering
        • Antalya Memorial Hospital
      • Sakarya, Tyrkiet (Türkiye), 54100
        • Rekruttering
        • Sakarya Training and Research Hospital
      • Augsburg, Tyskland, 86156
        • Rekruttering
        • Universitatsklinikum Augsburg
      • Berlin, Tyskland, 10715
        • Rekruttering
        • Praxis Am Volkspark
      • Chemnitz, Tyskland, 09116
        • Rekruttering
        • Klinikum Chemnitz Ggmbh
      • Essen, Tyskland, 45122
        • Rekruttering
        • Universitatsklinikum Essen (Aor)
      • Frankfurt am Main, Tyskland, 60389
        • Rekruttering
        • Centrum Fur Haematologie Und Onkologie Bethanien
      • Freiburg im Breisgau, Tyskland, 79106
        • Rekruttering
        • Universitatsklinikum Freiburg I Br Klinik Fur Innere Medizin I
      • Hamburg, Tyskland, 20251
        • Rekruttering
        • Universitatsklinikum Hamburg Eppendorf
      • Heidelberg, Tyskland, 69120
        • Rekruttering
        • Universitatsklinikum Heidelberg
      • Homburg, Tyskland, 66421
        • Rekruttering
        • Universitatsklinikum Des Saarlandes
      • Koblenz, Tyskland, 56068
        • Rekruttering
        • Invo Institut Fur Versorgungsforschung in Der Onkologie
      • Leipzig, Tyskland, 04103
        • Rekruttering
        • Universitaetsklinikum Leipzig Aor
      • Münster, Tyskland, 48149
        • Rekruttering
        • Universitatsklinikum Munster Medizinische Klinik A

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
  2. Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
  3. Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI).
  4. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
  5. Adequate liver function.
  6. Adequate blood clotting function.

Exclusion Criteria:

  1. Known prolymphocytic leukemia (defined per iwCLL 2018 as prolymphocytes comprising >55% of peripheral blood lymphocytes), or currently suspected or history of Richter's transformation within the last 5 years.
  2. Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 6 months.
  3. Known central nervous system involvement.
  4. Prior exposure to any BTK protein degraders.
  5. Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy.
  6. Clinically significant cardiovascular disease.
  7. Prior invasive fungal infection, except if patient agrees to receive secondary antifungal prophylaxis during the entire treatment period.
  8. Known contraindications to azole antifungal agents, including hypersensitivity reactions.
  9. Receiving systemic immunosuppressive therapy for a nonmalignant condition within 28 days before the first dose of study treatment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm A: Tacabrutideg monotherapy

Participants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met

Administered orally

Andre navne:
  • BGB-16673
Aktiv komparator: Arm B: Investigator's Choice

Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment.

Administered orally

Administered intravenously

Administered intravenously

Administered orally

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
Tidsramme: Approximately 36 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL).

Approximately 36 Months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall Survival (OS)
Tidsramme: Approximately 36 Months

OS is defined as time from the date of randomization to the date of death due to any cause.

Approximately 36 Months
PFS by the Investigator Assessment
Tidsramme: Approximately 36 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by the investigator using modified 2018 iwCLL criteria for participants with CLL and Lugano classification for participants with SLL

Approximately 36 Months
Rate of Partial Response with Lymphocytosis (PR-L) or Higher Determined by IRC and by Investigator Assessment
Tidsramme: Approximately 36 Months

Rate of PR-L or higher is defined as the percentage of participants with a best overall response of CR, CRi, nPR, PR, or PR-L as assessed by the IRC or by the Investigator

Approximately 36 Months
Duration of Response (DOR) by IRC and Investigator Assessment
Tidsramme: Approximately 36 Months

DOR is defined as the time from initial response to disease progression or death, whichever occurs first, as assessed by the IRC or by the investigator.

Approximately 36 Months
Time to Next Anti-CLL/SLL Treatment (TTNT)
Tidsramme: Approximately 36 Months

TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment.

Approximately 36 Months
Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales
Tidsramme: Approximately 24 Months

The symptom burden and physical condition will be measured by QLQ-CLL17. EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning. Each question is rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. The scores of each subscale are calculated based on the EORTC's protocol and then transformed to a 0 to 100 scale. Higher scores represent higher levels of symptom burden, physical condition/fatigue, or worries/fears about health and functioning.

Approximately 24 Months
Progression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC
Tidsramme: Approximately 36 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 iwCLL criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL) for participants with prior exposure to ncBTKi.

Approximately 36 Months
Overall Response Rate (ORR) by IRC and Investigator Assessment
Tidsramme: Approximately 36 Months

ORR is defined as the percentage of participants with best overall response of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial response (PR) as assessed by the IRC or by the investigator.

Approximately 36 Months
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Laboratory Abnormalities
Tidsramme: Approximately 36 Months

Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

Approximately 36 Months
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) Physical Functioning and Role Functioning Scales
Tidsramme: Approximately 24 Months

The EORTC QLQ-C30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales(fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7=Excellent (best). Higher scores in GHS and functional scales indicate better quality of life.

Approximately 24 Months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Study Director, BeOne Medicines

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. april 2025

Primær færdiggørelse (Anslået)

15. maj 2028

Studieafslutning (Anslået)

14. februar 2030

Datoer for studieregistrering

Først indsendt

21. februar 2025

Først indsendt, der opfyldte QC-kriterier

21. februar 2025

Først opslået (Faktiske)

26. februar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

IPD-delingstidsramme

See plan description

IPD-delingsadgangskriterier

See plan description

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .